Comparison of N-Terminal Pro B-Natriuretic Peptide and Echocardiographic Indices in Patients with Mitral Regurgitation by Hajsadeghi, Shokoufeh et al.
Clinical Medicine Insights: Cardiology 2010:4 111–116
doi:10.4137/CMC.S6062
This article is available from http://www.la-press.com.
© the author(s), publisher and licensee Libertas Academica Ltd.
This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
Open Access
Full open access to this and 
thousands of other papers at 
http://www.la-press.com. OriginAL reSeArCh
Clinical Medicine insights: Cardiology 2010:4  111
Clinical Medicine insights: Cardiology
comparison of n-Terminal pro B-natriuretic peptide 
and echocardiographic Indices in patients with Mitral 
Regurgitation
Shokoufeh hajsadeghi1, niloufar Samiei2, Masoud Moradi3, Maleki Majid2, Ladan Kashani3,  
Afsaneh Amani3, Arezoo Salami2, Melika Asefi3 and negin Farsi3
1rasoul Akram Medical Centre, Tehran, islamic republic of iran. 2Shaheed rajaei Cardiovascular Medical Centre, 
Tehran, islamic republic of iran. 3Medical Student research Committee, Faculty of Medicine, Tehran University of 
Medical Sciences, Tehran, islamic republic of iran. Corresponding author email: masoud_moradi65@yahoo.com
Abstract
Introduction: Echocardiographic indices can form the basis of the diagnosis of systolic and diastolic left ventricular (LV) dysfunction in 
patients with Mitral regurgitation (MR). However, using echocardiography alone may bring us to a diagnostic dead-end. The aim of this 
study was to compare N-Terminal pro B-natriuretic peptide (BNP) and echocardiographic indices in patients with mitral regurgitation.
Methods: 2D and Doppler echocardiography and BNP serum level were obtained from 54 patients with organic mild, moderate and 
severe MR.
Results: BNP levels were increased with symptoms in patients with mitral regurgitation (NYHAI: 5.7 ± 1.1, NYHAII: 6.9 ± 1.5, 
NYHAIII: 8.3 ± 2 pg/ml, P , 0.001). BNP plasma level were significantly correlated with MPI (myocardial performance index)
(r = 0.399, P = 0.004), and following echocardiographic indices: LVEDV (r = 0.45, P , 0.001), LVESV (r = 0.54, P , 0.001), LVEDD 
(r = 0.48, P , 0.001), LVESD (r = 0.54, P , 0.001), dp/dt (r = −0.32, P = 0.019) and SPAP (r = 0.4, P = 0.006).
Conclusion: The present study showed that BNP may be useful in patients with MR and may confirm echocardiographic indices.
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Introduction
Mitral regurgitation (MR) causes progressive systolic 
and diastolic left ventricular (LV) dysfunction,1,2 and 
has negative impacts on the prognosis of patients with 
MR.3–6  Understanding  the  degree  of  this  dysfunc-
tion and severity of regurgitation would be helpful 
to establish the best treatment strategy and improve 
patients’ survival.
Echocardiographic indices detection of significant 
regurgitation of mitral valves can form the basis of 
the diagnosis of mitral regurgitation and LV systolic 
and  diastolic  dysfunction. Although  assessment  of 
ventricular function using echocardiography may be 
difficult and can bring us to a diagnostic dead-end,7–9 
the use of multiple echocardiographic and hormonal 
parameters in combination can provide an accurate 
assessment of MR severity and LV dysfunction in 
most cases.
N-Terminal  pro  B-Natriuretic  Peptides  (NT-pro 
BNP)  are  synthesized  and  secreted  in  response  to 
increases in wall stress by cardiac myocytes.10,11 It 
has  been  shown  that  plasma  levels  of  the  NT-pro 
BNP which are elevated in myocardial infarction and 
heart failure patients are independent prognostic fac-
tors in numerous studies.12–14 In contrast, only a few 
studies have evaluated NT-pro BNP in valvular heart 
diseases. So the purpose of this study was to com-
pare NT-pro BNP and echocardiographic indices in 
patients with mitral regurgitation.
Methods
Patients
The  subjects  included  259  patients  who  were 
referred  to  the  Echocardiography  Department 
of  Shaheed  Rajaei  Cardiovascular  Medical  Cen-
tre (Tehran, Islamic Republic of Iran) for evalu-
ation  of  severity  of  mitral  regurgitation  from 
April  2009  to  March  2010.  205  patients  were 
excluded  (17  patients  had  mitral  stenosis,  13 
patients had right ventricular ischemia, 29 patients 
had  pulmonary  hypertension,  10  patients  had 
  aortic  stenosis,  35  patients  had  pulmonary  dis-
ease, 16 patients had hyperthyroidism, 22 patients 
had severe renal disease, 13 patients had age ,18, 
20 had poor imaging and 30 patients did not sub-
mit their informed consent). This left a study popu-
lation of 54 patients with mitral regurgitation (33 
females and 21 males; mean age, 52 ± 17 years).
Inclusion  criteria  for  the  study  were:  i)  sinus 
rhythm on electrocardiography with no   conduction 
disorder;  ii)  absence  of  cardiovascular  or  other 
  systemic disease; and iii) an upper limit of 120/80 for 
blood pressure at rest. All participants gave written 
informed consent for inclusion in the study. The study 
protocol was approved by the local Medical Ethics 
Committee.
n-terminal Pro-BnP measurement
Before the performance of echocardiography, a poly-
ethylene catheter was inserted percutaneously in a 
forearm vein for blood sampling and patient had been 
in a supine position. Samples were collected in EDTA 
tubes, immediately placed on ice, and transferred to 
the laboratory. Plasma levels of NT—pro-BNP were 
determined with Elecsys proBNP analyzer (measur-
ing range 5–35,000 pg/mL) using a chemilumines-
cent immunoassay kit (Roche Diagnostics).
echocardiograph
All patients underwent 2-dimensional echocardiogra-
phy using Vivid 7 (GE Vingmed Ultrasound, Horten, 
Norway), with the patient in left lateral decubitus. LV 
end systolic dimension (LVESD), volume (LVESV) 
and end diastolic volume (LVEDV) and dimension 
(LVEDD)  were  measured  as  recommended  by  the 
American society of echocardiography.15 The ejec-
tion fraction was calculated using the modified Simp-
son biplane method. LA volume was assessed using 
the biplane area-length method from apical 4- and 
2-chamber views at end systole from the frame pre-
ceding mitral valve opening and all other indices were 
measured according to American Society of Echocar-
diography guidelines.16
Myocardial  performance  index(MPI)  which  is 
defined as the sum of isovolumic contraction time and 
isovolumic relaxation time divided by the   ejection 
time was calculated (normal range: 0.39 ± 0.05) as 
described by Tei et al.17
Statistical analysis
The Independent sample t-test was used for compari-
son  of  parametric  variables,  one-way  ANOVA  for 
comparison  of  values  of  echocardiographic  indices 
and N-terminal pro BNP between three groups with 
MR. Distribution of BNP levels were skewed but were 
normal after logarithmic (Ln) transformation. Pearson Pro BnP and echocardiographic  indices in  regurgitation of mitral
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test is used to assess the correlation between plasma 
BNP levels and echocardiographic parameters. The 
areas under the receiver-operating   characteristic (ROC) 
curves were used to evaluate the diagnostic perfor-
mance  of  NT—pro-BNP  and  echocardiographic 
variables for the prediction of abnormality of MPI 
(MPI . 0.45) and were compared according to the 
method of Hanley and McNeil. Data are mean ± SD. 
P , 0.05 was considered significant. All tests were 
done with SPSS 16.0 (Statistical   Package for Social 
Sciences) for Microsoft Windows.
Results
The characteristics of 54 patients with mild (n = 8), 
moderate (n = 25) and severe (n = 21) MR are listed 
in Table 1.
BNP  levels  in  groups  with  mild,  moderate  and 
severe MR were 5.5 ± 1.6, 6.5 ± 1.5, 6.8 ± 1.6 pg/ml, 
  respectively  (P  =  0.162).  Myocardial  performance 
index were 0.44 ± 0.24, 0.42 ± 0.23 and 0.53 ± 0.28 in 
patients with mild, moderate and severe MR, respec-
tively. But there were no significant difference among 
3 groups (P = 0.404). BNP levels were increased with 
symptoms in patients with mitral regurgitation (NYHAI: 
5.7 ± 1.1, NYHAII: 6.9 ± 1.5, NYHAIII: 8.3 ± 2 pg/ml, 
P , 0.001). BNP plasma level were significantly cor-
related with MPI (r = 0.399, P = 0.004), and follow-
ing  echocardiographic  indices:  LVEDV  (r  =  0.45, 
P , 0.001), LVESV (r = 0.54, P , 0.001), LVEDD 
(r = 0.48, P , 0.001), LVESD (r = 0.54, P , 0.001), 
dp/dt (r = −0.32, P = 0.019), SPAP (r = 0.4, P = 0.006), 
LA dimension (r = 0.41, P = 0.004), LV mass (r = 0.34, 
P = 0.016) and negative correlation with LV ejection 
fraction (r = −0.543, P , 0.001), but there were no 
significant correlations between BNP plasma level and 
MR volume (P = 0.33), MR VC (P = 0.23), MR EROA 
(P = 0.34) and LA volume (P = 0.6).   Univariate anal-
ysis between MPI and echocardiographic indices are 
summarized in Table 2.
We categorized patients into two groups according 
to MPI cutoff level of 0.45. The areas under the ROC 
curve for NT—pro-BNP and echocardiographic mea-
sures to predict MPI abnormality are shown in   Figure 1. 
The areas were 0.722 (95% confidence interval [CI] 
0.57 to 0.87) for NT—pro-BNP, 0.792 (95% CI 0.65 
to 0.93) for LV end-systolic diameter, 0.49 (95% CI 
0.38 to 0.60) for LV end-diastolic diameter, 0.79 (95% 
CI 0.65 to 0.93) for LV end-systolic volume, and 0.76 
(95% CI 0.62 to 0.90) for LV end-diastolic volume. The 
sensitivity, specificity, and area under the ROC curve 
for abnormality of MPI by natriuretic peptide levels and 
echocardiographic measures are shown in Table 3.
Discussion
In the present study, we showed that BNP levels were 
increased with MR symptoms, and correlates with left 
Table 1. Baseline clinical characteristics.
Group 1 (mild) 
(n = 8)
Group 2 (moderate) 
(n = 25)
Group 3 (severe) 
(n = 21)
Men:Women 4:4 9:16 8:13
Age (years) 34 ± 16 59 ± 12 51 ± 19
heart rate (beat/min) 75 ± 18 75 ± 17 83 ± 22
BSA (m2) 1.6 ± 0.1 1.7 ± 0.2 1.6 ± 0.1
ejection fraction (%) 54 ± 9 43 ± 15 47 ± 16
LVeDD (mm) 5.1 ± 0.7 5.6 ± 0.9 5.8 ± 0.9
LVeSD (mm) 3.1 ± 0.8 3.9 ± 1 3.9 ± 1
LVeSV (ml) 57 ± 30 75 ± 41 76 ± 33
LVeDV (ml) 122 ± 38 131 ± 48 145 ± 44
LV mass (g/m2) 118 ± 54 141 ± 47 154 ± 65
LA dimension (mm) 3.8 ± 1 3.6 ± 0.6 4.3 ± 0.9
LA volume (ml) 48 ± 40 31 ± 18 62 ± 40
SPAP (mm hg) 27 ± 5 34 ± 9 40 ± 11
dp/dt 1830 ± 954 1609 ± 1056 1448 ± 927
Mitral annular diameter 3.5 ± 0.8 3.3 ± 0.4 3.5 ± 0.6
Abbreviations: LVeDD, left ventricular end diastolic dimension; LVeSD, left ventricular end systolic dimension; LVeDV, left ventricular end diastolic 
volume; LVeSV, Left ventricular end systolic volume; LV, left ventricular; LA, left atrium; SPAP, systolic pulmonary atrial pressure.hajsadeghi et al
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ventricular volumes and dimensions both in systole 
and diastole and some of the other echocardiographic 
indices. Also we showed that BNP levels had a same 
sensitivity and specificity in prediction of MPI abnor-
mality in comparison with other echocardiographic 
indices. Mitral regurgitation is a progressive disorder 
that leads to LV dilatation and dysfunction and reduced 
functional capacity in thes patients, and obtaining an 
accurate quantitative assessment of the severity and 
LV function of MR is technically demanding.18,19 The 
most internationally accepted methods to demonstrate 
prognosis of MR was LVEF but it has been seen that 
this index is more dependent on LV geometry and isn’t 
accurate. Previous study has shown that Tei index, a 
Doppler-derived echocardiographic index, is indepen-
dent of ventricular geometry, blood pressure and age. 
Since Tei index incorporates both systolic and diastolic 
ventricular function may provide a better assessment 
of the global LV function than LVEF.20
In the present study, we found that MPI correlates 
positively with left ventricular volumes and dimen-
sions both in systole and diastole, SPAP, LA dimen-
sion.  Dependency  of  MPI  to  preload  was  seen  in 
previous studies: Lutz and colleagues21 found that Tei 
index is only affected by the increase in preload in 
mechanically ventilated patients. Similarly, Moller and 
colleagues22 reported that Tei index is only affected 
by changes in load conditions in healthy volunteers. 
Bruch et al23 supported our result, describing positive 
correlation between MPI and LV end systolic volume. 
Correlation of MPI and dP/dt may indirectly describe 
parallel relation between dP/dt and isovolumic con-
traction time.
BNP as a neurohormone is secreted by the myo-
cardium  and  previous  studies  have  shown  that  its 
serum  level  elevated  in  patients  with  MR.24,25  We 
found that BNP were increased by symptoms sever-
ity and this is concordant to other studies showing 
increased  plasma  BNP  levels  with  higher  NYHA 
classes.26,27 We also found positive relation between 
MPI and BNP level which both increased by systolic 
and diastolic dysfunction.
Our data showed that there is no statistically sig-
nificant difference in myocardial performance index 
and BNP of the patients with mild, moderate or severe 
MR. In other words, neither myocardial performance 
index  nor  BNP  levels  can  predict  the  severity  of 
mitral regurgitation. This finding supports the pre-
vious studies which believed in patients with mitral 
regurgitation BNP activation is a result of alterations 
in hemodynamic, atrial and ventricular status rather 
than the degree of regurgitation alone.
When we have chosen cut point level of 0.45 for 
MPI based on Ono and colleague's20 study we could 
define a cut point for N-terminal pro BNP serum level 
and some of the mentioned echocardiographic indi-
ces to differentiate normal and abnormal MPI. To the 
best of our knowledge, this study is the first one in the 
medical literature that gives such information in mitral 
Table  2.  Univariate  analysis  between  MPi  and  other 
echocardiographic indices.
r P
ejection fraction −0.54 ,0.001
LVeDD 0.54 ,0.001
LVeSD 0.55 ,0.001
LVeSV 0.6 ,0.001
LVeDV 0.47 ,0.001
LV mass 0.36 0.009
LA dimension 0.31 0.029
LA volume −0.57 0.7
Mr erOA 0.252 0.08
Mr VC 0.17 0.23
Mr volume 0.114 0.43
SPAP 0.31 0.03
dp/dt −0.34 0.013
Mitral annular diameter 0.440 0.002
Abbreviations:  LVeDD,  left  ventricular  end  diastolic  dimension; 
LVeSD, left ventricular end systolic dimension; LVeDV, left ventricular 
end diastolic volume; LVeSV, left ventricular end systolic volume; LV, left 
ventricular; LA, left atrium; SPAP, systolic  pulmonary  atrial  pressure; 
Mr, mitral regurgitation.
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Figure 1. Diagonal segments are produced by ties.Pro BnP and echocardiographic  indices in  regurgitation of mitral
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regurgitation. Based on our results, an N-  Terminal 
proBNP serum level of more than 603 pmol/l can 
show the abnormality of MPI with 71% sensitivity 
and 73% specificity.
Furthermore, calculation and comparison of area 
under  ROC  curves  for  N-Terminal  proBNP  and 
echocardiographic measures such as LV end-diastolic 
volume,  LV  end-systolic  volume,  LV  end-systolic 
dimension and LV end-diastolic dimension showed 
that there is no significant clinical difference between 
these indices such that one may be chosen as the best 
one for prediction of MPI abnormality. And because 
BNP measurement is easier, it costs less than echocar-
diography and intra observer viability may be useful 
to use as a hormonal marker in patients with MR.
Limitation
It  may  be  better  to  measure  diastolic  echocardio-
graphic  indices  due  to  systolic  and  demonstrated 
relation of them with BNP which representative both 
systolic and diastolic function. Also further studies 
with  larger  population  may  lead  to  more  accurate 
results.
conclusion
This study showed that BNP measurement has the 
same sensitivity and specificity as echocardiographic 
indices and may be used as a hormonal factor for the 
evaluation of patients with MR in combination with 
echocardiography.
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